Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation
Authors
Keywords
-
Journal
BONE MARROW TRANSPLANTATION
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-10-31
DOI
10.1038/s41409-019-0729-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?
- (2019) Shalin Kothari et al. Current Hematologic Malignancy Reports
- Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1
- (2019) H. Pfeifer et al. LEUKEMIA
- Comparison of Population-Based Observational Studies With Randomized Trials in Oncology
- (2019) Payal D. Soni et al. JOURNAL OF CLINICAL ONCOLOGY
- Chronic myeloid leukemia stem cells
- (2019) Mohammad Houshmand et al. LEUKEMIA
- Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma
- (2019) Susan Bal et al. BRITISH JOURNAL OF HAEMATOLOGY
- Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy
- (2019) Zachariah DeFilipp et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians
- (2019) J. Gauthier et al. BONE MARROW TRANSPLANTATION
- Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances
- (2019) Irene Della Starza et al. Frontiers in Oncology
- BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee
- (2018) Sarah A. Holstein et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
- (2018) Gerrit J. Schuurhuis et al. BLOOD
- Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches
- (2018) Ciprian Tomuleasa et al. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
- Effect of More vs Less Frequent Follow-up Testing on Overall and Colorectal Cancer–Specific Mortality in Patients With Stage II or III Colorectal Cancer
- (2018) Peer Wille-Jørgensen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association Between Intensity of Posttreatment Surveillance Testing and Detection of Recurrence in Patients With Colorectal Cancer
- (2018) Rebecca A. Snyder et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000)
- (2018) Martin Schrappe et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Minimal Residual Disease in Acute Myeloid Leukemia
- (2018) Mojca Jongen-Lavrencic et al. NEW ENGLAND JOURNAL OF MEDICINE
- MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment
- (2018) Ola Landgren et al. SEMINARS IN HEMATOLOGY
- The challenging task of enumerating blasts in the bone marrow
- (2018) Aaron Hodes et al. SEMINARS IN HEMATOLOGY
- Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
- (2018) Sebastian Giebel et al. BONE MARROW TRANSPLANTATION
- How good are we at predicting the fate of someone with acute myeloid leukaemia?
- (2017) E Estey et al. LEUKEMIA
- Measurable residual disease testing in acute myeloid leukaemia
- (2017) C S Hourigan et al. LEUKEMIA
- Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
- (2017) J Flores-Montero et al. LEUKEMIA
- Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia
- (2017) Carolyn Owen et al. LEUKEMIA & LYMPHOMA
- Minimal Residual Disease Eradication in CML: Does It Really Matter?
- (2017) Srinivas K. Tantravahi et al. Current Hematologic Malignancy Reports
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia
- (2016) Prisca Theunissen et al. BLOOD
- Effect of measurable (‘minimal’) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia
- (2016) M Othus et al. LEUKEMIA
- Best Practices in Chronic Myeloid Leukemia Monitoring and Management
- (2016) Simona Soverini et al. ONCOLOGIST
- Minimal Residual Disease and Childhood Leukemia: Standard of Care Recommendations From the Pediatric Oncology Group of Ontario MRD Working Group
- (2016) Uma H. Athale et al. PEDIATRIC BLOOD & CANCER
- Quantifying the impact of different approaches for handling continuous predictors on the performance of a prognostic model
- (2016) Gary S. Collins et al. STATISTICS IN MEDICINE
- Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL
- (2015) P. A. Thompson et al. BLOOD
- Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies
- (2015) J. J. M. van Dongen et al. BLOOD
- Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial
- (2014) Ajay Vora et al. LANCET ONCOLOGY
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- (2013) S. H. Petersdorf et al. BLOOD
- High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study
- (2013) Monique Terwijn et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial
- (2013) Ajay Vora et al. LANCET ONCOLOGY
- Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks
- (2013) Paul Blanche et al. STATISTICS IN MEDICINE
- The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach
- (2012) Jan J. Cornelissen et al. Nature Reviews Clinical Oncology
- Evaluating Prognostic Accuracy of Biomarkers under Competing Risk
- (2011) Yingye Zheng et al. BIOMETRICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More